HCPCS J7354 is officially defined as "Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg)." HCPCS J7354 is referenced in 5 tracked payer policy changes from Florida Blue, Aetna, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7354 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Florida Blue is expanding their Physician-Administered Drug Program (PADP) effective March 1, 2026, requiring preservice reviews for 25 specific specialty drug codes before administration. Claims will be denied without prior authorization, and providers cannot bill patients for denied charges.
Cantharidin (Ycanth) is considered medically necessary for commercial medical plans for the topical treatment of molluscum contagiosum when all criteria are met: the member is 2 years of age or older, the member has a diagnosis of molluscum contagiosum, Ycanth is not used for oral, mucosal, or ophthalmic lesions, a healthcare professional who has received instruction and training administers it, and no more than 2 applicators are used in a single treatment session. Continuation of therapy is considered medically necessary for up to 4 treatment sessions (cycles) per infection when the same criteria are met. More than 4 treatment sessions and use for members under 2 years of age are considered experimental, investigational, or unproven, and all other indications are considered experimental, investigational, or unproven.
BCBS Mississippi has established that Ycanth (cantharidin) for treating molluscum contagiosum is considered not medically necessary as covered alternatives exist. All services related to delivery and administration will be denied without prior authorization approval through BCBSMS PA review process.
Mississippi State and School Employees' Health Insurance Plan has determined that Ycanth (cantharidin) for treating molluscum contagiosum is not medically necessary because other covered treatment options are available. Both the drug and its administration services will be denied as not medically necessary.
Premera HMO medical policies were revised effective April 1, 2024 for drugs including Padcev, Braftovi, Imbruvica, Jaypirca, generic gefitinib, Injectafer, Zelsuvmi and Vabysmo, and new policies made total facet arthroplasty for lumbar spinal stenosis and CO2 fractional laser ablation for hypertrophic scars and keloids investigational. Carelon Medical Benefits Management guideline updates for radiation therapy and advanced imaging apply to dates of service on and after April 14, 2024, and genetic testing updates apply to dates of service on and after June 30, 2024. Coding changes effective April 1, 2024 added codes that now require review for medical necessity, investigational status or prior authorization, moved Carelon Management Genetic Testing codes to Carelon review, and terminated codes including Q4244, C9160 and C9162.
Watch J7354
Get one email when a payer policy names J7354, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J7354
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J7354 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.